Fretting over Vertex CF drug Orkambi? Nah
This article was originally published in Scrip
Executive Summary
If investors were worried over the FDA's concerns about whether Vertex's investigational cystic fibrosis drug Orkambi – a combination of the firm's marketed CF medicine Kalydeco (ivacaftor) with a new agent, lumacaftor – worked well enough for the intended population, they sure did not show it on 8 May.